Today Zimmer Biomet announced the acquisition of CD Diagnostics, a move that will further strengthen the company’s competitive position in the musculoskeletal market. The two companies formed a co-development and marketing partnership in 2012, and as part of the agreement, Zimmer Biomet marketed CD Diagnostics’ Synovasure Periprosthetic Joint Infection (PJI) test, which provides more accuracy in detecting periprosthetic infection and is touted as the first and only test specifically designed and validated for diagnosing PJI.
“I formed CD Diagnostics to solve the frustrating problem of diagnosing PJI and the complications associated with misdiagnosis, including the pain and incremental costs-of-care following joint replacement surgery,” said Carl Deirmengian, M.D., scientific founder of CD Diagnostics in a press release.
Zimmer Biomet’s Group President of Joint Reconstruction Dan Williamson added, “As value-based healthcare replaces fee-for-service models, there will be a growing need for diagnostics that can either prevent or minimize costly complications, or personalize the course of treatment to speed up recovery time and optimize the patient experience and, ultimately, the patient’s outcome.”
Zimmer Biomet did not disclose the financial terms of the transaction.